RNAAtrium Therapeutics, Inc.
- Market cap
- $140.27M
- as of 2026-10-23
- Latest close
- $8.20
- as of 2026-10-23
- Sector
- Healthcare
- as of 2026-10-24
- Industry
- Biotechnology
- as of 2026-10-24
Cluster
No cluster in the last 90 days under the default rule (14d · ≥2 insiders · all roles).
Form 4 historysince 2026-03-02
| Insider | Traded | Filed | Type | Shares | Price | Value | Owned after | 10b5-1 plan | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Hoyos Rocio MartinChief Strategy Officer | Sep 18 | Sep 22 | F | 8,320 | $8.95 | $74,464 | 38,340 | No | Form 4 |
| Winslow Brendan R.Chief Financial Officer | Sep 18 | Sep 22 | F | 6,742 | $8.95 | $60,341 | 36,859 | No | Form 4 |
| Gallagher Kathleen P.See Remarks | Sep 18 | Sep 22 | F | 11,632 | $8.95 | $104,106 | 119,729 | No | Form 4 |
| Kenney StephanieSee Remarks | Sep 18 | Sep 22 | F | 2,375 | $8.95 | $21,256 | 33,085 | No | Form 4 |
| Boyce Sarah | Sep 18 | Sep 22 | F | 126,418 | $8.95 | $1,131,441 | 138,668 | No | Form 4 |
| Flanagan W. Michael | Sep 18 | Sep 22 | F | 22,812 | $8.95 | $204,167 | 31,974 | No | Form 4 |
| Hughes Steven GeorgeChief Medical Officer | Sep 18 | Sep 22 | F | 21,459 | $8.95 | $192,058 | 51,638 | No | Form 4 |
| Younis HusamChief Scientific Officer | Sep 18 | Sep 22 | F | 11,216 | $8.95 | $100,383 | 41,441 | No | Form 4 |
| Younis HusamChief Scientific Officer | Apr 20 | Apr 22 | A | 30,000 | $0.00 | $0 | 52,657 | No | Form 4 |
| Younis HusamChief Scientific Officer | Apr 20 | Apr 22 | A · derivative | 60,000 | $14.30 | $858,000 | 60,000 | No | Form 4 |
| Hoyos Rocio MartinChief Strategy Officer | Apr 20 | Apr 22 | A | 30,000 | $0.00 | $0 | 46,660 | No | Form 4 |
| Hoyos Rocio MartinChief Strategy Officer | Apr 20 | Apr 22 | A · derivative | 60,000 | $14.30 | $858,000 | 60,000 | No | Form 4 |
| Gallagher Kathleen P.See Remarks | Apr 20 | Apr 22 | A | 102,500 | $0.00 | $0 | 131,361 | No | Form 4 |
| Gallagher Kathleen P.See Remarks | Apr 20 | Apr 22 | A · derivative | 205,000 | $14.30 | $2,931,500 | 205,000 | No | Form 4 |
| Winslow Brendan R.Chief Financial Officer | Apr 20 | Apr 22 | A | 30,000 | $0.00 | $0 | 43,601 | No | Form 4 |
| Winslow Brendan R.Chief Financial Officer | Apr 20 | Apr 22 | A · derivative | 60,000 | $14.30 | $858,000 | 60,000 | No | Form 4 |
| Hughes Steven GeorgeChief Medical Officer | Apr 20 | Apr 22 | A | 30,000 | $0.00 | $0 | 73,097 | No | Form 4 |
| Hughes Steven GeorgeChief Medical Officer | Apr 20 | Apr 22 | A · derivative | 60,000 | $14.30 | $858,000 | 60,000 | No | Form 4 |
| Kenney StephanieSee Remarks | Apr 20 | Apr 22 | A | 30,000 | $0.00 | $0 | 35,460 | No | Form 4 |
| Kenney StephanieSee Remarks | Apr 20 | Apr 22 | A · derivative | 60,000 | $14.30 | $858,000 | 60,000 | No | Form 4 |
| Skerjanec Simona | Feb 27 | Mar 2 | A · derivative | 20,000 | $14.75 | $295,000 | 20,000 | No | Form 4 |
| Flanagan W. Michael | Feb 27 | Mar 2 | A · derivative | 20,000 | $14.75 | $295,000 | 20,000 | No | Form 4 |
| Wilson Troy Edward | Feb 27 | Mar 2 | A · derivative | 20,000 | $14.75 | $295,000 | 20,000 | No | Form 4 |
| Boess Carsten | Feb 27 | Mar 2 | A · derivative | 20,000 | $14.75 | $295,000 | 20,000 | No | Form 4 |
| Boyce Sarah | Feb 27 | Mar 2 | A · derivative | 20,000 | $14.75 | $295,000 | 20,000 | No | Form 4 |